1. Role of mitochondria as the gardens of cell death

   • Ryungsa Kim
   • Manabu Emi
   • Kazuaki Tanabe

   Review 21 September 2005 Pages: 545 - 553

   

2. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial

   • Rupert Bartsch
   • Catharina Wenzel
   • Guenther G. Steger

   Original Article 23 August 2005 Pages: 554 - 558

   

3. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer

   • Kathleen E. Rodgers
   • Jamie Oliver
   • Gere S. diZerega

   Original Article 12 August 2005 Pages: 559 - 568

   

4. CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines

   • Lori J. Pobst
   • Matthew M. Ames

   Original Article 11 August 2005 Pages: 569 - 576

   

5. The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer

   • Yutaka Ogata
   • Keiko Matono
   • Kazuo Shirouzu

   Original Article 20 August 2005 Pages: 577 - 583

   

6. Antimetastatic effect of a lipophilic ascorbic acid derivative with antioxidation through inhibition of tumor invasion

   • Jianwen Liu
   • Xiaodong Zhang
   • Yuhong Ren

   Original Article 02 August 2005 Pages: 584 - 590

   

7. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin

   • Haifeng Song
   • Jin Zhang
   • Jie Ma

   Original Article 30 August 2005 Pages: 591 - 598

   

8. Thalidomide does not interact with P-glycoprotein

   • Christian Zimmermann
   • Heike Gutmann
   • Juergen Drewe

   Original Article 01 September 2005 Pages: 599 - 606

   

9. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl

   • Mao Li
   • Hui Wang
   • Ruiwen Zhang

   Original Article 06 December 2005 Pages: 607 - 614

   

10. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients

    • Alessandra Fabi
    • Gianluigi Ferretti
    • Francesco Cognetti

    Original Article 15 September 2005 Pages: 615 - 623

11. Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin’s and non-Hodgkin’s lymphoma and a preliminary study on the toxicity of etoposide associated with LDE

    • Ketlin V. Pinheiro
    • Vania T. M. Hungria
    • Raul C. Maranhão

    Original Article 25 August 2005 Pages: 624 - 630

    

12. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors

    • William C. Zamboni
    • Sanjay Goel
    • Sridhar Mani

    Original Article 05 October 2005 Pages: 631 - 639

    

13. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer

    • V. Heinemann
    • H. J. Stemmler
    • G. Rauthe

    Original Article 15 September 2005 Pages: 640 - 646

    

14. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer

    • Takuji Okusaka
    • Hiroshi Ishii
    • Toshio Tsuyuguchi

    Original Article 02 September 2005 Pages: 647 - 653

    

15. Pharmacokinetics and biodistribution of the camptothecin–polymer conjugate IT-101 in rats and tumor-bearing mice

    • Thomas Schluep
    • Jianjun Cheng
    • Mark E. Davis

    Original Article 26 August 2005 Pages: 654 - 662

    

16. Failure of neutrophil chemotactic function in breast cancer patients treated with chemotherapy

    • Maria Angélica O. Mendonça
    • Fernando Q. Cunha
    • Beatriz M. Tavares-Murta

    Original Article 27 August 2005 Pages: 663 - 670

    

17. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors

    • Matthew G. Fury
    • Lee M. Krug
    • Naiyer A. Rizvi

    Original Article 31 August 2005 Pages: 671 - 677

18. A phase I study of monohydroxyethylrutoside in healthy volunteers

    • Anja M. Willems
    • Anne M. Bruynzeel
    • Wim J. van der Vijgh

    Original Article 01 September 2005 Pages: 678 - 684

    

19. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

    • Chetan Lathia
    • John Lettieri
    • Pavur Sundaresan

    Original Article 25 August 2005 Pages: 685 - 692

    

20. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models

    • Kaori F. -Ouchi
    • Mieko Yanagisawa
    • Yutaka Tanaka

    Original Article 16 December 2005 Pages: 693 - 702

    

21. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C

    • Paul H. Sugarbaker
    • O. Anthony Stuart
    • C. Pablo Carmignani

    Original Article 11 August 2005 Pages: 703 - 708